Navigation Links
QIAGEN Acquires Exclusive Licence for Key PI3K gene
Date:2/8/2010

VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays. Research has shown that variation in the PI3K gene could be a key biomarker for use as a companion diagnostic with certain cancer treatments. The studies suggest that mutations in the PI3K oncogene are predictive for the success of certain treatments of patients suffering from lung, breast, colorectal and other cancers. QIAGEN has an active PI3K assay development and partnering program with pharmaceutical companies to develop and market tests for new cancer drug candidates. Financial details were not disclosed.

QIAGEN already markets a PI3K test for research use. This test is based on real-time polymerase chain reaction (RT-PCR), a widely available technology to make DNA sequences visible through amplification. The assay, which uses technology that allows a very significant sensitivity, detects mutations frequently missed by sequencing methods.

The patent for PI3K mutations in human cancers was initially filed by researchers at Johns Hopkins who assessed the biomarker during their evaluation of tyrosine kinase inhibitors targeting the EGFR (Epidermal Growth Factor Receptor) pathway. Various EGFR inhibiting drugs have shown to be not effective in cancer patients with mutations in genes of the EGFR pathway (EGFR, K-RAS, B-RAF etc.). QIAGEN already markets several tests determining the mutation status in oncogenes. This portfolio includes tests for mutations of K-RAS and B-RAF, which are indicative for metastatic colorectal, lung and other cancers. The K-RAS test is CE-marked for companion diagnostic use with EGFR inhibitors Vectibix(R) and Erbitux(R) and is expected to be submitted for FDA approval shortly.

"This license agreement is another step forward for QIAGEN and for the use of novel therapeutics that rely on the widespread availability of the required PI3K companion diagnostic test", said Peer M. Schatz, CEO of QIAGEN. "We are looking forward to developing drug-diagnostic combinations together with pharmaceutical partners for the selection of the right patient for the right medicine. This concept allows cancer patients to receive better treatments and can support healthcare systems to provide the most useful therapies in cost effective ways."

QIAGEN is active in more than 15 partnerships with pharmaceutical and large biotech companies in the field of personalized healthcare, including AstraZeneca, Merck, Amgen, Lilly, Boehringer-Ingelheim and Pfizer. QIAGEN has developed and markets approximately 20 companion diagnostics assays in personalized healthcare and has a strong pipeline targeting to further expand this leading franchise.

About Companion Diagnostics (CDx)

Companion Dx are integral to the part of personalized healthcare which allows physicians to determine patients' potential responses to drug treatment. These diagnostic tests are developed together with drugs for particular populations. By testing for specific genetic variations related to certain biomarkers, health professionals can customize their treatments to achieve the best possible therapeutic results and avoid unnecessary treatments.

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.

QIAGEN SAFE HARBOR STATEMENT

Statements contained in this release that are not historical facts are forward-looking statements, including statements about our products, markets, strategy and operating results. Such statements are based on current expectations that involve risks and uncertainties including, but not limited to, those associated with: management of growth and international operations (including currency fluctuations and logistics), variability of our operating results, commercial development of our markets (including applied testing, clinical and academic research, proteomics, women's health/HPV testing, molecular diagnostics, personalized healthcare and companion diagnostics), our relationships with customers, suppliers and strategic partners, competition, changes in technology, fluctuations in demand, regulatory requirements, identifying, developing and producing integrated products differentiated from our competitors' products, market acceptance of our products, and integration of acquired technologies and businesses. For further information, refer to our filings with the SEC, including our latest Form 20-F. Information in this release is as of the date of the release, and we undertake no duty to update this information unless required by law.

    Contacts:

    Dr. Solveigh Mahler
    Director Investor Relations
    QIAGEN N.V.
    +49-2103-29-11710
    e-mail: solveigh.maehler@qiagen.com

    Albert F. Fleury
    Director Corporate Finance and
    Investor Relations North America
    QIAGEN N.V.
    +1-301-944-7028
    e-mail: albert.fleury@qiagen.com

    Dr. Thomas Theuringer
    Associate Director Public Relations
    QIAGEN GmbH
    +49-2103-29-11826
    email: thomas.theuringer@qiagen.com

    Joanne Cross
    Marketing Manager
    DxS - a QIAGEN Company
    Phone: +44(0)7540-121-673
    Email: joanne.cross@qiagen.com

SOURCE Qiagen


'/>"/>
SOURCE Qiagen
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
2. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11
3. Plexus Awarded Development Contract With QIAGEN
4. QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata
5. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
6. QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations
7. SciQuest Announces Strategic Alliance with QIAGEN
8. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2008 Financial Results Call Set for August 5
9. Webcast Alert: QIAGEN N.V. Announces First Quarter 2008 Earnings Conference Call
10. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Fourth Quarter and Year End 2007 Earnings and 2008 Guidance Conference Call on the Web
11. Cell Biosciences Acquires Protein Forest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... Lajollacooks4u, San Diego’s premier team building events and cooking ... new program offerings and company expansion. , This is largely due to ... of over 30 people. Ever since, Lajollacooks4u has seen significant demand for its services ...
(Date:12/8/2016)... December 8, 2016 AskLinkerReports.com has published ... titled Global Amyloglucosidase Industry 2016 Market Research Report. From a ... industry chain overview are all covered in the report. This ... investment return analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)... MOINES, Iowa , Dec. 8, 2016 Eurofins announces ... US Food and President of Eurofins Scientific Inc. (ESI). ... Division with his proven professional and entrepreneurial experience in leading international ... in the US food testing market to uphold Eurofins, status as ... ...
(Date:12/8/2016)... England , December 8, 2016 ... das Unternehmen für Molekulargenetik, erweitert seine Palette an ... myPanel™ NGS Custom FH Panels, das ein schnelles ... (FH) ermöglicht. Das Panel bietet eine Erkennung von ... Variations (CNV) mit einem einzigen kleinen Panel und ...
Breaking Biology Technology:
(Date:12/6/2016)... Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") today ... principal amount of its 1.414% senior unsecured notes due 2022 ... notes due 2026. The closing of the ... the satisfaction of customary closing conditions.  The notes will pay ... The Company intends to use the net proceeds from the ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe ... announced BioLock , an electrocardiogram (ECG) biosensor ... monitoring, a key IoT asset. The smart system ... a vehicle,s steering wheel and mobile devices to ... touch. As vehicle technology advances, so ...
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s ... ... DERMALOG is Germany's largest Multi-Biometric ... Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is ...
Breaking Biology News(10 mins):